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ABSTRACT
Malaria, caused by the parasite Plasmodium falciparum, has a long history as a global
health threat. The vector-borne disease causes millions of deaths yearly, especially in
developing countries with tropical climates that facilitate transmission. Compounding the
problem is the emergence of drug-resistant strains due to overuse of outdated treatments. New
compounds with antiplasmodial activity are needed to be developed as effective drugs against
malaria.
The hypothesis for this project is that marine microorganisms have a high likelihood of
yielding novel antiplasmodial chemotypes because of their high diversity, which has not yet
been explored for antimalarial development. In this project, microbes harvested and fermented
by the Harbor Branch Oceanographic Institute in Fort Pierce, Florida were explored as sources
for antiplasmodial natural products. Using a SYBR Green I fluorescence-based assay, 1,000
microbial extracts were screened for inhibition of the multidrug-resistant Plasmodium falciparum
strain Dd2. Dose-response analysis was performed on 46 fractions from isolates whose extracts
demonstrated ≥ 70% inhibition of Dd2 at 1 µg/mL.
To evaluate cytotoxicity, the MTS cell viability assay was used to calculate IC50 of
extracts from active isolates in NIH/3T3 embryonic mouse fibroblasts. Several extracts
demonstrated low IC50 in Dd2 and high IC50 in 3T3, suggesting that they contain potential lead
antimalarial compounds. Extracts with high selectivity indices (potent plasmodial inhibition
with low mammalian toxicity) have been prioritized for dereplication, with the goal of
identifying novel active components that can be developed as antimalarial drugs.
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CHAPTER ONE: PLASMODIUM FALCIPARUM MALARIA
Background
Malaria is an infectious disease caused by the Plasmodium species of eukaryotic parasites,
which invade hepatocytes and erythrocytes in humans. The vector-borne infectious agent is
transmitted to humans through the bite of an infected female Anopheles mosquito.
Consequently, malaria is most common in tropical regions where the warm, moist climate
favors mosquito breeding. Although most malaria cases are reported in central Africa, its
distribution pattern shows that it is common in economically challenged areas worldwide. It is
estimated that malaria affects 225 million people and causes more than 1 million deaths
annually [1]. Since malaria has established itself as a global health threat, effective treatments
are necessary to control the spread of infection and ease the burden of disease.

Life Cycle
Mosquito Stage
The main vector for Plasmodium spp. is the female Anopheles mosquito, which ingests
male or female gametocytes into its esophagus during a blood meal from an infected host. In the
midgut of the mosquito, gametocytes undergo sexual reproduction to form zygotes. Meiotic
recombination during gametogenesis, along with random mating in the mosquito midgut,
results in extensive genetic variation among new parasites that may contribute to rapid
development of drug resistance [2]. Zygotes develop into ookinetes, which multiply and form
oocyts on the surface of the midgut. Parasites within the oocyts then develop into sporozoites
and migrate through the epithelium of the midgut to the salivary glands of the mosquito.
During a blood meal, sporozoites are carried out of the salivary glands in the saliva and are
incidentally injected into a new mammalian host [3].
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Hepatocyte Stage
Sporozoites from anopheline mosquitoes that have entered the bloodstream during a
blood meal invade the liver, where they multiply exponentially (Figure 1). Knockout studies [4]
and live-cell imaging [5] reveal that in some Plasmodium spp., sporozoites traverse and lyse
phagocytic Kupffer cells to reach the hepatocytes. Critical to parasite survival within the
hepatocyte is formation of the parasitophorous vacuole membrane (PVM), which encapsulates
invasive sporozoites as they differentiate into exponentially reproductive trophozoites. Genes
that are upregulated in infective sporozoites (UIS) are necessary for reproduction within
hepatocytes; to prevent ectopic merozoite formation, mRNA transcripts of UIS genes are
generally silenced until triggered by an unknown mechanism [6].
Erythrocyte Stage
P. vivax and P. ovale are known for having prolonged stages during which dormant
parasites, called hypnozoites, are latent in the hepatocytes (Figure 1). Whether from the
sporozoite or hypnozoite stage, differentiation into trophozoites results in massive production
and packaging of merozoites, with breakdown of the PVM and lysis of hepatocytes [6]. When
merozoites emerge from the liver and invade red blood cells, the symptomatic intraerythrocytic
phase has begun. In the erythrocyte, merozoites are able to metabolize hemoglobin while
undergoing various stages of development (Figure 1). The parasite matures through the ring,
trophozoite, and schizont stages before the schizont segments into numerous merozoites
approximately 48 hours after invasion (72 hours in P. malariae) [2]. A few merozoites develop
into male and female gametocytes, ready to infect anopheline mosquitoes during a blood meal
and undergo sexual reproduction in the midgut (Figure 1).
2

Figure 1: Summary of Plasmodium life cycle [7].
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Pathophysiology
During the hepatic stages, while trophozoites are multiplying, the patient may be
asymptomatic. But once the merozoites rupture the erythrocyte and enter the bloodstream, a
process that takes 5-7 days, clinical manifestations appear [6]. An immune response mediated
by tumor necrosis factor (TNF) results in generalized “flu-like” symptoms such as fever,
malaise, and body aches. Since the erythrocytic stages are cyclic, releasing merozoites every 48
to 72 hours, fevers may be separated by a corresponding time period. In severe disease with
high parasite load, merozoites may be released from hepatocytes and erythrocytes in an
asynchronous pattern, resulting in an erratic pattern of frequent fevers [2]. As the disease
progresses, inflammatory tissue damage reaches the pulmonary and gastrointestinal organs,
especially in adults. Sequestration in the placenta during pregnancy brings added risk of
morbidity, both maternal (profound anemia, severe malaria, or cerebral malaria) and neonatal
(low birth weight, stillbirth, or congenital malaria) [8].
Exceptional susceptibility of young children to P. falciparum malaria may be explained
by age-differential immune responses to parasitic infection. Asynchronous immunologic assays
comparing the immunity in adults and children indicate that in both groups, initial exposure
produces an inflammatory response mediated by Th1 cells, as evidenced by increased levels of
IL-12 and IF-γ. In young children, the innate response is more pronounced, involving dendritic
antigen-presenting cells’ response to toll-like receptors, and activation of NK cells and T cells by
IF-γ [9]. Compared to adults, children have higher incidence of cerebral malaria, severe anemia,
and metabolic acidosis [10]. In some parts of Africa, the childhood mortality rate of P. falciparum
malaria is up to 20%, even in children who receive recommended treatment [2].
4

As the species most responsible for morbidity and mortality, Plasmodium falciparum has
several characteristics that contribute to its virulence. Infection with P. falciparum has been
known to reach high parasite loads, up to 1012 in some cases. Pronounced immune responses
and erythrocytic lysis induced by the parasite result in bone marrow suppression and severe
anemia [2]. One life-threatening complication unique to P. falciparum infection is cerebral
malaria, which is often fatal in children: to avoid clearance from the body by hemolysis and
antibody-mediated phagocytosis in the spleen, P. falciparum merozoites have been found to
sequester erythrocytes and complete their life cycle in terminal venules of the central nervous
system. The resulting inflammation and neuronal damage often results in developmental delay
and cognitive impairment even in subclinical cases [11].

Epidemiology
P. falciparum malaria is endemic in many parts of central Africa. One measure of
prevalence and immunity is the entomological inoculation rate (EIR), which is the number of
times an individual has been bitten by a malaria vector in one year. Global distribution of EIR
indicates that in West and Central Africa, where parasitic rate is highest, EIR can reach 100 or
greater, indicating a link between transmission (EIR) and endemicity. In areas characterized by
a consistent level of transmission and EIR >10, resistance to malaria may develop at a young age
[12]. In these individuals, constant low-level exposure to parasitic antigens has resulted in
immunity. However, children under the age of 10 are still considered a vulnerable population:
many in this group have been found to lack antibodies against P. falciparum on the surface of
their red blood cells [9]. Even in regions where malaria is endemic, young children and
pregnant women are most susceptible.
5

Of the five predominant Plasmodium species (P. ovale, P. vivax, P. knowlesi, P. malariae,
and P. falciparum), P. vivax and P. falciparum are the most common: the other three are limited to
parts of Africa and Papua New Guinea [13]. Although all species can cause malaria, only P.
falciparum is associated with severe morbidity and mortality. Populations at risk for malaria can
be identified by the parasite rate (PR), the number of individuals per 100 individuals in an age
group who are positive for P. falciparum parasitemia. Data from the Malaria Atlas Project shows
global parasitic rates in children between the ages of 2 and 10, the population with the most risk
for morbidity and mortality (Figure 2). Children at highest risk for P. falciparum infection (PfPR
>40%, and up to 76.1%), a population of 327 million, are concentrated in Central Africa, from
West Africa to Mozambique and Madagascar [12]. Correlation with tropical regions is the result
of warmer temperatures that facilitate development within the vector, and moist climates with
standing water suitable for mosquito breeding [14].

6

Figure 2: Global distribution of P. falciparum malaria by endemicity class [12].
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Economic Burden
Regions in which malaria is endemic correlate closely with areas of poverty. Malarious
countries have approximately one-fifth the gross domestic product (GDP) per compared to
nations with an insignificant malaria burden. Expenditures related to malaria are extensive,
both private (mosquito nets and medical care) and public (vector control and research) [14].
Like other childhood diseases, malaria depletes human capital: aside from the direct toll on
human life, child mortality may reduce gross national product (GNP) by increasing fertility
rates and number of dependents [15]. Higher fertility influences medical expenses due to
recommendations for bed nets and prophylactic medications during pregnancy [8]. Since travel
to malarious regions carries risk of disease and the requirement of prophylactic regimens,
tourism industries and labor forces can also bear the burden of malaria [14].
But while the disease itself contributes to economic hardship, poverty can also
undermine efforts to eradicate malaria. In developed countries, strong financial resources
supported efforts to control transmission, including drainage of standing water in the
environment, improved screening and insulation in housing, and consistent utilization of
insecticides [14]. Due to widespread poverty in malaria-endemic countries, these measures can
be difficult to implement. In drug discovery, economic challenges necessitate that novel
antimalarial drugs be synthesized at a relatively low cost to facilitate distribution [16]. Poverty
also limits access to the most effective existing treatments: to maximize the efficiency of
government-sponsored medications, the World Health Organization (WHO) recommends the
administration of subsidized artemisinin combination therapy (ACT) to young children only
[17]. Cost effectiveness is an essential consideration in any effort to prevent and treat malaria.
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Prevention
Preventing P. falciparum infection begins with reducing vector-mediated transmission.
Anopheles gambiae, remarkable for its high human bite rates, is the primary vector in endemic
African areas [12]. To prevent insect bites, WHO recommends the use of insecticide-treated nets
(ITNs), a cost-effective measure that has been shown to reduce childhood morbidity by 50% and
overall mortality by 17% [18]. More promising are LLINs (long-lasting insecticidal nets), which
can reduce transmission up to 90% by embedding chemicals in mesh fibers [19]. Indoor residual
spraying (IRS) of insecticides, including dichloro-diphenyl-trichloroethane (DDT), pyrethroids,
carbamates, and organophosphates, can further decrease infection [20]. Studies correlating bed
net availability, funding, and household use suggest that the best approach to yield high
compliance is a combination of fully-subsidized burst campaigns and partially-subsidized
maintenance measures [19].
Developing a vaccine against P. falciparum malaria has proven difficult. Vaccines can
potentially induce immunity at various stages of plasmodial development (Figure 3). The most
advanced malaria vaccine is RTS,S-AS01, which induces immunity to circumsporozoite protein
(CSP) in the pre-erythrocytic liver phase: it has recently undergone Phase III clinical trials [21].
Other targets include merozoite surface protein (MSP), expressed in the asexual erythrocytic
phase, and antigens on the surfaces of gametocytes and ookinetes during to the sexual vector
transmission phase [10]. Challenges in vaccine development include selection for strains that
evade the immune response mounted against injected antigens, as monitored by molecular
surveillance studies in pre-erythrocytic phase and asexual phase vaccines [22].
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Figure 3: Targets in malaria vaccine development [10].
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CHAPTER TWO: ANTIMALARIAL DRUGS AND RESISTANCE
Current Antimalarial Drugs
Amino Alcohols
Antimalarials can be classified based on their structure-based mechanism of action.
Blood schizonticides, including quinine, target Plasmodium in its erythrocytic stages. Since its
discovery centuries ago from the bark of the cinchona tree (Cinchona officinalis), quinine has
historically been the mainstay of malaria treatment. An aryl amino alcohol, quinine localizes to
the digestive vacuole and blocks the polymerization of heme, a toxic product of hemoglobin
proteolysis, and its mineralization to hemozoin. This may occur by forming toxic complexes
with heme that perforate the parasitic cell membrane [23]. A barrier to quinine monotherapy
has been its severe side effects collectively known as cinchonism, involving headache, nausea,
and disturbances in hearing and vision. Today, quinine is primarily used as adjunct treatment
with other antimalarials, especially in severe malaria [24]. Mefloquine is a 4-methanoquinoline
with a structure similar to quinine (Figure 4). It has a long half life and has been used for longterm prophylaxis, albeit with side effects which prevent widespread use [25]. Related amino
alcohols lumefantrine and halofantrine are also thought to interfere with metabolism and
detoxification of hemoglobin. Both were synthesized independently to mimic the structure of
quinine and mefloquine, and are currently used in combination therapy [7].
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Figure 4: Structures of amino alcohols [7].
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4-Aminoquinolines
Chloroquine is a 4-aminoquinoline that acts as an amphiphilic, diprotic weak base in the
cellular environment (Figure 5). Due to an intracellular gradient characterized by acidic pH in
the parasitic food vacuole, protonated chloroquine migrates to the vacuole where hemoglobin is
metabolized [23]. Once transported into the vacuole, it disrupts heme detoxification through a
mechanism similar to that of amino alcohols. The related drug amodiaquine has comparative
effectiveness, but with undesirable side effects. Since chloroquine and amodiaquine exhibit
structural and functional similarities to quinine and mefloquine, cross-resistance among amino
alcohols and 4-aminoquinolines is common [26]. Along with newer 4-aminoquinolines
pyronaridine and piperaquine, amodiaquine is used in combination therapy where chloroquine
resistance is widespread [27].
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Figure 5: Structures of 4-aminoquinolines [7].
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8-Aminoquinolines
While blood schizonticides such as quinine and chloroquine inhibit P. falciparum in the
erythrocytic phase, tissue schizonticides eliminate hepatocyte infection. These drugs include the
8-aminoquinolines primaquine, pamaquine, and tafenoquine (Figure 6). Doxycycline and
tetracycline, commonly used antibiotics with tissue schizonticide activity, are sometimes
included in this functional class. Tissue schizonticides are the only known class of antimalarials
that affects P. vivax and P. ovale hypnozoites in the liver [7]. Hypnozoites are favorable drug
targets because the low parasitic burden at this asymptomatic stage increases the probability of
complete clearance before global inflammation and organ damage occurs. Primaquine also
exhibits gametocidal activity in P. falciparum [28]. Due to their mechanism of action, 8aminoquinolines can be administered to prevent hypnozoite relapse in patients with past P.
vivax and P. ovale malaria [29].

15

Figure 6: Structures of 8-aminoquinolines [7].
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Antifolates
Antifolate agents, which interfere with folic acid metabolism and utilization, were first
explored as antitumor agents. Their efficiency as inhibitors of rapid cell proliferation was
eventually extended to antiparasitic therapy. Class I antifolate agents, which target
dihydropteroate synthase (DHPS), include the sulfone and sulfonamide antibiotics. These
compounds target the ability of P. falciparum to synthesize folic acid through de novo pathways
shared by many prokaryotic microorganisms [30]. Dapsone, a sulfone derivative, is the oldest
antifolate agent (discovered in 1908) and the most commonly used in human chemotherapy.
Class II antifolate agents inhibit dihydrofolate reductase (DHFR) in eukaryotic metabolic
pathways, including those involved in malignancy. Proguanil, a class II antifolate first studied
in the 1940s, is still used in combination therapy today. Pyrimethamine, a proguanil analog, is
the most widely used antifolate agent in P. falciparum malaria. The related compound
chlorproguanil can also be used as adjunct treatment.
Class I and class II antifolate agents are often used in combination for synergistic
inhibition of folate metabolism and biosynthesis. Pyrimethamine, a long-acting class II
antifolate, has been combined with class I sulfadoxine (Fansidar), sulfalene (Metakelfin), or
dapsone (Maloprim) [31]. Dapsone is also used with chlorproguanil in a unique but effective
combination of older drugs [32]. Proguanil is marketed in combination with atovaquone
(Malarone) as effective prophylaxis in Plasmodium-naïve travelers to endemic areas.
Atovaquone itself is an antiparasitic agent that interferes with aerobic respiration in eukaryotic
microorganisms (Figure 7). By blocking electron transport to the cytochrome bc1 complex
(coenzyme Q), atovaquone inhibits oxidative metabolism in parasitic mitochondria [33].
17

Figure 7: Structures of atovaquone and antifolate agents [7].
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Endoperoxides
As resistance to quinine derivatives and antifolates escalated, a solution was discovered
by a collaboration of Chinese scientists in the form of artemisinin, a natural product of sweet
wormwood (Artemisia annua, known as Qinghao). According to a recipe from the fourth century
B. C., a water extract from Qinghao could cure fever [16]. Artemisinin derivatives include
artesunate, artemether, artimotil, and dihydroartemisinin, the active metabolite (Figure 8).
Molecularly, these drugs are endoperoxide-containing sesquiterpene lactones which are
believed to generate toxic alkoxide radicals by interacting with Fe2+ produced during heme
metabolism [34]. The targets of radicals released in this manner are controversial, but may
include the sarcoplasmic and endoplasmic reticulum calcium ATP transporter (SERCA). Other
mechanisms of action may include degradation of phospholipid membranes in the parasite [35].
Artemisinins are unique in their ability to rapidly clear almost all erythrocytic stages of
P. falciparum. Endoperoxides also target gametocytes, blocking a key step in cyclic transmission
to Anopheles mosquito vectors [7]. To prevent resistance and compensate for the short half life of
artemisinins, they are exclusively administered as ACT, in conjunction with other antimalarial
drugs [16]. Established ACT regimens form the foundation of modern malaria therapy and
include artemether-lumefantrine, artesunate-amodiaquine, artesunate-pyrinaridine, artesunatemefloquine, dihydroartemisinin-piperaquine, and artesunate-chlorproguanil-dapsone [10]. In
anticipation of resistance to artemisinins, and to take advantage of their potent mechanism of
action, new antimalarials with similar structure have been synthesized, including artemisone,
OZ277, and PAT103 (Figure 8).

19

Figure 8: Structures of endoperoxides [7].
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Emergent Antimalarial Resistance
One of the barriers to effective utilization of existing malaria treatments is the emergence
of drug-resistant P. falciparum strains. Malaria mortality increased dramatically in the 1980s
once P. falciparum became resistant to the 8-aminoquinoline chloroquine (and many of its
derivatives), the primary drug used at the time. Resistance eventually developed against the
antifolate combination sulfadoxine-pyrimethamine, the preferred alternative to chloroquine
[13]. Today, recommended treatment for uncomplicated malaria in endemic areas usually
includes ACT to prevent resistance and improve efficacy. However, artemisinin resistance has
also evolved, as evidenced by recent cases in Cambodia where P. falciparum clearance was
significantly reduced despite artemisinin therapy [36].
Mechanisms
Several categories of drug resistance have been identified, many of which correspond
with the mechanism and structure of a specific drug. Resistance against antifolates can evolve
through point mutations or over-expression of folate pathway enzymes PfDHP (class I
resistance) and/or PfDHFR (class II resistance). Similarly, mutations in cytochrome b complex
may decrease the therapeutic effects of atovaquone [13]. Polymorphisms in the P. falciparum
chloroquine resistance transport gene (pfcrt) results in accelerated chloroquine clearance from
the food vacuole [37]. Chloroquine resistance transporter (PfCRT) has 10 transmembrane
domains and localizes to the digestive vacuole membrane, where it may act as a partition,
channel, or carrier for protonated chloroquine. Cross-resistance of mutant strains with
amodiaquine, quinine, and mefloquine indicates a broadly structure-specific function [23].
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Multi-drug resistance transporter 1 (PfMDRT1), encoded by pfmdrt1, is implicated in
resistance to drugs of unrelated classes, including quinine, chloroquine, mefloquine,
artemisinin, and halofantrine (Figure 9). As a membrane-bound ATP-binding cassette (ABC),
PfMDRT1 may prevent retention and promote efflux of various drugs, toxins, and ions from the
cytoplasm. Since PfMDRT1 is specifically embedded in the digestive vacuole membrane with its
ATPase facing the cytoplasm, it is likely involved in transporting drugs into the vacuole. The
phenotype of resistance due to mutations in PfMDRT1 depends on the residue affected:
transport may be increased (sequestering toxic compounds) or decreased (preventing
disruption of heme metabolism). Overexpression also promotes sequestration and may be
associated with resistance against artemisinin and even mefloquine, which has been shown to
have cytotoxic effects outside the digestive vacuole [23].

22

Figure 9: P. falciparum multi-drug resistance protein 1 (PfMDR1). (A) Mutated residues implicated in
resistance highlighted in red. (B) ATPase transport into the digestive vacuole [23].
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Artemisinins
Drug resistance against artemisinin and its derivatives is the most alarming trend that
has emerged in recent years. In vitro growth analysis of clinically resistant strains reveals that
artemisinin only retards the development of Plasmodium parasites in the ring stage, although it
eradicates the later trophozoite and schizont stages. Dormant ring parasites, in which the
vacuole is absent and both the nucleus and cytoplasm are condensed, could re-activate and
cause recrudescence of parasitemia up to 20 days later [38]. Many clinically resistant strains fail
to demonstrate resistance in laboratory studies: this phenomenon is attributed to the failure of
dormant parasites to utilize growth indicators (condensed cytoplasm) or interact with DNAintercalating dyes (condensed nucleus) [39].
Resistance to artemisinin may develop in stages, beginning with the increased survival
of rings (although those that mature further are killed) and progressing as resistant genotypes
predominate the adult stages. Treating resistant strains with mefloquine in combination with
artemisinin reduced recrudescence, ostensibly by killing dormant rings: these in vitro results
support the use of ACT [38]. Genetic analysis of artemisinin-resistant strains implicates mutated
drug transporters, including PfMDR1, although these mutations alone are not sufficient to cause
clinical resistance [40].
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CHAPTER THREE: ANTIMALARIAL DRUG DISCOVERY
Recent Efforts
To maximize efficiency of available treatment and combat drug resistance in P.
falciparum, the World Health Organization has made recommendations for drug utilization and
development. Their campaign emphasizes the need to confirm malaria cases, promote
efficacious treatments, and conduct outcome surveillance. For neonatal prophylaxis in Africa,
intermittent preventive treatment during pregnancy (IPTp) with sulfadoxine-pyrimethamine
(SP) controls parasitemia and anemia, prevent symptoms during pregnancy, and reduces infant
mortality. To reduce P. falciparum transmission, primaquine should be administered. Regarding
the discovery and development of new antimalarials, WHO emphasizes the need for drugs that
interrupt gametocyte-mediated transmission, prevent hypnozoite-mediated relapse, have
extended half-lives for chemoprophylaxis, and provide single-dose eradication [18].
Current projects in antimalarial drug discovery often involve modifying existing
compounds. Many Phase III options for eradication of severe malaria involve ACT variants [41].
Compounds experimentally administered during pregnancy include antimalarials like ACT,
mefloquine, and azithromycin (an antibiotic that synergizes with chloroquine). Development of
compounds similar in structure and action to artemisinin and primaquine are also underway
[42]. The synthesis of artemisinin-aminoquinoline hybrid molecules has been presented as a
novel approach, providing nanomolar IC50 in vitro and in vivo [43]. Although the utilization of
known antimalarial classes limits their use for resistant strains, hybrids may establish a
precedent for increasing bioavailability by linking novel chemotypes to known scaffolds.
25

While these efforts concentrate on existing scaffolds, the focus of phenotypic screening is
on novel chemotypes. In the past five years, ground-breaking screenings of small-molecule
libraries have identified antimalarial classes through cell-based methods. Collaboration between
the Scripps Research Institute and the Novartis Institute of Tropical Diseases [44] eventually led
to the optimization of spiroindolones and imidazolopiperazines for clinical trials [45]. At St.
Jude’s Children’s Research Hospital, screening resulted in the discovery of dihydropyridines,
dihydroisoquinolones, and diaminonaphthoquinones, all of which show promising
bioavailability [46]. Screening the GlaxoSmithKline library yielding more than 10,000 validated
hits [47], of which the cyclopropyl carboxamides have undergone additional development.
These results highlight the benefits of collaboration between academic and industrial
institutions in providing starting points for lead optimization and clinical studies.

Rational Approach
Most drugs in the antimalarial pipeline are directed against the erythrocytic stage.
However, pathways involved in resistance are potential therapeutic targets: an inhibitor of
these mechanisms can be administered in combination with an existing drug [48]. Another
favorable target with high potential selectivity for parasitic inhibition is P. falciparum
dihydroorotate dehydrogenase (DHODH), involved in nucleoside biosynthesis [49]. High
potency and selectivity can be achieved by targeting pathways unique to the parasite, such as
those in the apicoplast, an organelle similar to the chloroplast in plant cells. Fosmidomycin, an
inhibitor of isoprenoid biosynthesis in the apicoplast, has entered Phase II clinical trials [50].
Apicoplast fatty acid biosynthesis is a promising target for rational drug discovery as well [51].
These and other pathways are summarized in Table 1.
26

Table 1: Targets in antimalarial rational drug design [7].
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Screening Approach
The development of high-throughput screening (HTS) methods that can screen large
libraries of pharmacological compounds for inhibition of P. falciparum revolutionized
antimalarial drug discovery, offering a productive alternative to rational drug design. As
previously mentioned, hit rates approaching 0.5% were reported in a landmark screen that
identified hundreds of potent scaffolds out of 1.7 million compounds [45]. Screening the nearly
2 million compounds in GlaxoSmithKlein’s chemical library yielded thousands of hits: many of
these compounds showed little structural similarity to existing inhibitors [47]. Even against
multiple drug-resistant strains of Plasmodium, hundreds of compounds in a stringent screen for
potency and selectivity were validated as hits [46].
In Vitro Assays
To screen for antiplasmodial activity, whole-cell in vitro assays directly assess culture
viability after the addition of compounds. Radioactive assays of [3H]ethanolamine or
[3H]hypoxanthine incorporation remain the gold standard in screening, but their disadvantages
include safety hazards, multiple steps, and high costs [52]. Efficient HTS of potential drug
compounds requires an assay that is rapid, reliable, and relatively inexpensive: SYBR Green I
fluorescence-based assays meet these criteria [53]. However, HTS using radioactive isotopes or
SYBR Green I select against apicoplast inhibitors such as antibiotics, which exert their effect
after 2 parasite life cycles, or 96 hours [54]. Enzyme-linked immunosorbent assays (ELISA) that
target lactate dehydrogenase (LDH) have been developed [55], as well as flow cytometry assays
that stain nucleic acids with ethidium bromide or DAPI. An added benefit of flow cytometry is
selective gating to identify effects on specific parasitic stages [52].
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Characteristics of potential leads that merit early prioritization include potent inhibition,
acceptable half-life, selectivity against human cells, and low cost of synthesis [7]. HTS has
yielded such compounds, including spiroindolones entering Phase I just 3 years after discovery
[56]. But while HTS against erythrocytic P. falciparum selects for blood schizonticides, the
eradication of malaria requires drugs that target hypnozoites, hepatic sporozoites, and
gametocytes as well. To address the need for assays at these stages, recent studies have
investigated the activity of common antimalarials throughout the Plasmodium life cycle using
novel methods. After drug addition, gametocytes were inspected for exflagellation and ookinete
formation or fed to Anopheles mosquitoes to investigate sporogony and oocyst formation.
Hepatic infection was also modeled to screen compounds for inhibition of liver schizonts [57].
Natural Products
In the history of antimalarials, natural products have proven to be effective sources of
drugs, most notably quinine and artemisinin. Using natural product-derived molecular
scaffolds is not limited to antimalarial drug discovery. Cephalosporins and penicillins, also
derived from secondary metabolites, have been used for years as antibiotics. In fact, most antiinfective and anti-cancer drugs have been derived from natural products [58]. However, only a
small percentage of these natural products are from marine life, perhaps due to the perspective
that the exposure to terrestrial agents helps soil microbes produce the most efficient antibiotics.
Furthermore, harvesting marine natural products presents a significant challenge. But marine
metabolites have been discovered that inhibit methicillin-resistant Staphylococcus aureus (MRSA)
and vancomycin-resistant Enterococcus (VRE) [59]. Aquatic organisms can be productive sources
of drugs against even the most problematic infectious agents.
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Biodiversity in marine ecosystems increases the potential for discovering novel bioactive
compounds. Many marine natural products demonstrate antiplasmodial activity, including
alkaloids from the sponges Micromonospora and Phloeodictyon, which exhibit inhibition
comparable to chloroquine. Peptide derivatives from the mollusks Dolabella and Elysia inhibit
plasmodial reproduction. Like artemisinins, endoperoxides from Diacarnus and Plakortis
sponges generate radicals. Terpenoids, which interfere with heme sequestration, are produced
by Acanthella sponges, Streptomyces bacteria, Sphaerococcus seaweed, and Sarcophyton coral. To
decrease cytotoxicity and improve bioavailability, chemical modifications of these compounds
have been carried out [60]. One possible approach to discovering bioactive compounds is
screening libraries of natural product-like compounds to increase hit rate and eliminate
positively charged or cytotoxic moieties early in the screening process [61].
Though many promising natural products derived from marine life have been isolated
from invertebrates, the active compounds derived from sponges and corals may actually be
secondary metabolites of microbes that are involved in a symbiotic relationship with the
invertebrates. Studies have shown that the cell cycle inhibitor phorboxazole A, originally
attributed to the Phorbas sponge, is most likely produced by colonizing cyanobacteria on its
surface or by the sponge itself through genomic data integrated from the symbiont.
Salinosporamide A, a drug compound used experimentally against multiple myeloma in
clinical trials, is derived from Salinispora actinomycetes found in deep-sea samples. Notably,
Salinispora was a previously unknown bacterial species, a fact that highlights the untapped
nature of marine biodiversity [62]. Exploration of marine microbes can lead to the discovery of
secondary metabolites that exhibit antiplasmodial activity.
30

CHAPTER FOUR: MATERIALS AND METHODS
HBOI Marine Microbial Extracts
Isolated marine habitats contain unique microbes and metabolites that have yet to be
discovered. The Harbor Branch Oceanographic Institute (HBOI) utilizes equipment that can
harvest samples from low-temperature, high-pressure areas up to 900 meters below the surface.
They have developed methods that enable efficient recovery and cultivation of microbes from
these samples [63]. Over 19,000 microbial isolates comprise the Harbor Branch Marine
Microorganism Culture Collection (HBMMCC). Data from 16S rRNA sequence analysis on
these isolates suggested the possibility of novel species [64]. The presence of unique microbes,
along with familiar organisms that thrive in a unique environmental niche, increases the
probability that previously undiscovered metabolites will be produced by microorganisms in
the HBMMCC.
The microbial extracts screened for antiplasmodial activity in this project are derived
from diverse bacterial and fungal selections from the HBMMCC. Fungi, actinomycetes, and
unique bacteria, which have the highest probability of yielding potential hits, were prioritized
for fermentation. Microbes have been cultured under both static conditions (in moistened rice)
and shake conditions (in SYZ media and potato dextrose broth). These environments are
associated with increased secretion of secondary metabolites in marine microorganisms.
Furthermore, extracts from microbes cultured under static conditions were found to contain
structurally unique compounds upon chemical analysis of components. Fermented cultures
were extracted with various solvents, including methanol, heptanes, and ethyl acetate. For this
project, HBOI prepared 1,000 marine microbial extracts for to be screened against P. falciparum.
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One thousand marine microbial extracts were received from HBOI in twelve 96-well
plates (labeled “HBOI.44” through “HBOI.55”) with 0.2 mg of freeze-dried sample in each well
containing an extract. To prepare the extracts for screening, each sample was re-suspended at
room temperature in 200 µL of 200-proof ethanol, yielding an initial concentration of 1000
µg/mL. Extracts at 1000 µg/mL were stored at -80°C, and 200-proof ethanol was used
exclusively as the diluent when extracts were serially diluted for dose-response analysis. For
extracts that were insoluble in ethanol, suspensions were vortexed for 3 seconds and transferred
immediately to avoid false negative results due to sedimentation. The scheme for antimalarial
drug discovery from marine microbial extracts is summarized in Figure 10.
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Figure 10: HBOI – UCF drug discovery scheme.
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Culturing Plasmodium falciparum Dd2
The drug-resistant P. falciparum strain Dd2 is known to be chloroquine-, mefloquine-,
and pyrimethamine-resistant, but artemisinin-sensitive. Using a version of the traditional
culture method [65], Dd2 was cultured in RPMI media with L-glutamine (Invitrogen), 26 mM
NaHCO3, 25 mM HEPES, 25 mg/L gentamicin,15 mg/L hypoxanthine, 2% dextrose, and 0.5%
Albumax I. The erythrocytic stages of P. falciparum Dd2 were incubated at 37°C at 5% CO2 and
95% air. Every 2 days, culture media was changed and a blood smear was prepared to observe
parasitic invasion of erythrocytes by Giemsa staining. To determine parasitemia, the following
formula was applied in five fields of view, and the average was calculated to obtain
parasitemia: [% parasitemia] = [number of parasites in erythrocytes] / [number of erythrocytes] *
[100%]. Culture with parasitemia ≥ 10% were split to half volume and replenished using culture
media and erythrocytes (type A+, leukocyte-reduced, and irradiated, from the Central Florida
Blood Bank) to maintain hematocrit at 4%.

SYBR Green I Assay
Antimalarial assays that use fluorescent DNA-intercalating dyes, including YOYO-1,
PicoGreen, and SYBR Green I, have gained widespread use in medium- and high-throughput
screening. Exploiting the lack of DNA in erythrocytes, these protocols utilize molecules that
selectively intercalate double-stranded nucleic acids. The resulting activated complex emits
light at a wavelength that can be detected and quantified by a plate reader [53]. Due to its ability
to report the amount of parasitic DNA present after incubation with test compounds, SYBR
Green I was used in this project to screen for inhibition of P. falciparum Dd2, generate doseresponse curves, and determine the IC50 in Dd2 of extracts from active isolates.
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To quantify inhibition of Dd2, 1 µL of each extract at the appropriate concentration was
added to 99 µL of asynchronous Dd2 culture at 1% parasitemia and 2% hematocrit, for a 1:100
final dilution. In 96-well microplates, extracts were plated, combined with culture, and mixed
on an orbital shaker for 2 minutes. Included in each plate were negative control wells (culture
only) and positive control wells (1 µL of chloroquine 10 µM, approximately five-fold IC50 of
chloroquine in Dd2) [66]. Plates were incubated in culture conditions for 72 hours (about 1.5
erythrocytic life cycles, to compensate for asynchrony) [52], then frozen for at least 12 hours at 80°C. After thawing plates at room temperature, 100 mL of SYBR Green I lysis buffer (20 mM
Tris-HCl, 5 mM EDTA, 0.8% Triton X-100, 0.08% saponin, and 0.01% SYBR Green I) was added
to each well. Plates were protected from light and incubated at 37°C for 30 minutes, then
fluorescence was read at 485 nm excitation and 530 nm emission in a Synergy H4 Hybrid multimode microplate reader (Biotek). All experiments were performed in triplicate.

Culturing NIH/3T3 Fibroblasts
NIH/3T3 is a mouse embryonic fibroblast line chosen for counter-screening in
mammalian cells because it exhibits robust in vitro growth favorable for viability assays. 3T3
cells were cultured in DMEM with added 10% fetal bovine serum (FBS), 1% Pen-Strep, and 1
mM sodium pyruvate. Cultures were incubated at 37°C at 5% CO2 and 95% air. Since 3T3 cells
have poor contact inhibition, cultures were observed every 2 days for confluency. High-density
confluent cells were rinsed with phosphate-buffered saline, mobilized using trypsin-EDTA, and
split to one-fifth volume in culture media. When necessary for cytotoxicity assays, concentration
of live 3T3 cells was calculated by diluting trypsinized cells, adding trypan blue dye, and
counting cells that exclude trypan blue (indicating intact membranes) in a hemocytometer.
35

MTS Cell Viability Assay
To investigate the potential for cytotoxicity against human tissue, extracts that exhibited
were counter-screened against NIH/3T3 murine embryonic fibroblasts using a version of the 3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) cell viability assay, which has been
successfully used in cytotoxicity studies for almost 20 years [67]. The one-step MTS protocol
used in this project introduces 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4sulfophenyl)-2H-tetrazolium salt (MTS) as a substrate that can be metabolized by mitochondrial
dehydrogenase enzymes in viable eukaryotic cells. Reduction of MTS forms an insoluble purple
formazan, which can be detected by measuring absorbance at an appropriate wavelength.
Absorbance is then correlated with survival of metabolically active cells. Although the MTS
assay is less sensitive than the MTT assay, its results are reliable for use in medium- and highthroughput screens [68].
For this project, 50 µL of NIH/3T3 mouse fibroblasts in culture media were seeded into
384-well clear-bottom microplates for a total number of 2,500 cells per well. After the plates
were incubated in culture conditions for 24 hours, 0.5 µL of extract suspended in 200-proof
ethanol was added at the appropriate concentration. Negative control wells (no additive) and
positive control wells (0.5 µL of 5-fluorouracil) were also included on each plate. Plates were
then incubated in culture conditions for an additional 48 hours before 50 µL of CellTiter 96
AQueous non-radioactive cell proliferation assay reagent (Promega) was added at room
temperature. After 3 hours of incubation in culture conditions, absorbance was measured at 490
nm by a Synergy H4 Hybrid multi-mode microplate reader (Biotek). All experiments were
performed in triplicate.
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Reliability
To assess the quality of data obtained through the SYBR Green I and MTS protocols, Zfactor was calculated for each microplate. The Z-factor is a measure of data consistency
developed for high-throughput screening. Triplicate data from positive and negative control
wells were used to calculate Z-factor according to the following formula: [Z-factor] = 1 ± [(3σn 3σp) / (µn – µp)], where σn and σp are the standard deviation of negative and positive control
values obtained by fluorescence emission (SYBR Green I assay) or absorbance (MTS assay),
while µn and µp are the mean values for negative and positive control wells. Analysis yields a Zfactor between 0 and 1; values between 0.5 and 1 indicate valid results, and values close to 1
suggest ideal conditions for reliability [69]. For this project, a Z-factor ≥ 0.7 for each 96- or 384well plate was the criterion for statistical analysis. Experiments yielding a Z-factor < 0.7 must be
repeated with new Dd2 or 3T3 culture.

Dose-Response Analysis
Dose-response analysis against P. falciparum Dd2 and NIH/3T3 fibroblasts was
performed to confirm potency, evaluate cytotoxicity, and estimate the therapeutic index. For
Dd2, the SYBR Green I protocol was used to screen extracts at 2.5 µg/mL, 1.0 µg/mL, 0.5
µg/mL, 0.25 µg/mL, and 0.10 µg/mL. These concentrations were chosen to generate doseresponse curves from which half-maximal inhibitory concentrations (IC50) ≤ 1 µg/mL could be
calculated. Select fractions with IC50 < 0.10 µg/mL were also screened at 0.25 µg/mL, 0.10
µg/mL, 0.05 µg/mL, 0.025 µg/mL, and 0.010 µg/mL. For 3T3, extracts were screened using the
MTS protocol at 50 µg/mL, 25 µg/mL, 10 µg/mL, 5 µg/mL, and 2.5 µg/mL. These
concentrations were designed to generate IC50 > 2.5 µg/mL.
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To screen marine microbial extracts for active inhibition of P. falciparum Dd2, samples
were screened in a two-step process. For the first screen, final concentration of the extracts in
each well after the addition of Dd2 culture was 10 µg/mL: in the second screen, final
concentration in each well was reduced to 1 µg/mL. If plates produced acceptable data (Z-score
≥ 0.7), percent inhibition was calculated using the following formula: [% inhibition] = [µn – µX] /
[µn – µp] * [100%], where µX is the mean fluorescence emission of the triplicate values obtained
for each extract. Samples that demonstrated inhibition ≥ 70% at an initial concentration of 10
µg/mL were selected to undergo the second screen. Fractions with ≥ 70% inhibition at 1 µg/mL
were classified as active extracts.
To determine the IC50 of active extracts in P. falciparum Dd2 and NIH/3T3 fibroblasts,
data obtained through SYBR Green I and MTS assays (which met the criterion of Z-factor ≥ 0.7)
was analyzed using Microsoft GraphPad Prism. Nonlinear regression was performed on
triplicate values normalized to positive (0%) and negative (100%) controls, and data was fitted
to a log[inhibitor] vs. response curve of variable slope. For all assays, maximal inhibition was
taken to be ≈ 0%. IC50 values for each extract against Dd2 and 3T3 were determined from doseresponse curves generated in GraphPad Prism. Dose-response analysis enabled quantification
of selectivity, or the relationship between the IC50 of an extract in Dd2 (plasmodial inhibition)
and its IC50 in 3T3 (mammalian cytotoxicity) [60]. Extracts with high selectivity exhibit high
potency against P. falciparum while permitting high cell viability of embryonic mouse
fibroblasts. Selectivity index was calculated using the following formula: [fold selectivity] = [IC50
in 3T3] / [IC50 in Dd2].
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CHAPTER FIVE: RESULTS AND DISCUSSION
Primary Screening of Marine Microbial Extracts
To increase efficiency and reduce the probability of screening inactive extracts at low
concentrations, a primary screen at a higher concentration was conducted. The SYBR Green I
fluorescence-based assay was used to screen 1,000 extracts for the ability to inhibit intraerythrocytic growth of P. falciparum Dd2 at a concentration of 10 µg/mL. Of the 1,000 fractions
screened for significant plasmodial inhibition, 145 reported ≥ 70% inhibition at 10 µg/mL, a hit
rate of 14.5%. These results, as well as the active wells from each plate, are listed in Table 2.
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# of Actives
7
15
17
10
8
14
13
11
13
5
19
13
145

Plate
44
45
46
47
48
49
50
51
52
53
54
55

C2
A2
D1
B2
F6
A1
A4
A1
A2
A7
B7
C1

Active Wells (>70% inhibition @ 10 μg/mL)
C4 D8 G1 G2 G3 G7
A3 A4 B1 B2 B3 B11 C1 C2 C3 C6 C7 E1 H1 H2
D5 D6 F6 F8 F9 F11 G2 G6 G7 G9 G10 H1 H2 H3 H5 H7
B3 B5 C4 C5 C6 D4 D7 D8 D10
G1 G2 G4 G5 H2 H5 H7
A2 A3 A4 A5 A6 A7 A8 A9 F2 F5 G8 G9 H3
A5 A8 B3 B4 C1 C5 E4 F2 F4 F5 F11 G1
A2 A7 A10A11 B1 B2 B5 B6 B7 D2
A3 A8 A11 B1 C10E10 F3 F7 G1 G5 H3 H11
E5 E8 E9 E10
B8 B9 C3 D4 D5 E5 E11 F1 F2 F11 G4 G7 G8 G10 H3 H4 H7 H8
C2 C3 C6 C7 C8 C9 C10C11 D1 D2 D3 E1

Table 2: Active marine microbial extracts at 10 µg/mL.
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Stringent Screening of Marine Microbial Extracts
Based on the results of the first screen, extracts that exhibited significant inhibition at 10
µg/mL were analyzed in a second screening at a concentration of 1 µg/mL. Of the 145
microbial extracts that were active in the first screening, 22 demonstrated ≥ 70% inhibition P.
falciparum Dd2 at 1 µg/mL, a hit rate of 15.2% or 2.2% overall. The identities of active extracts,
along with the solvent used in their extraction, are summarized in Table 3. Also listed are wells
that did not demonstrate significant (≥ 70%) inhibition at the second screening concentration,
but have a source microorganism identical to that of an active extract. These samples differ from
the active extract hits in fermentation method and/or extraction solvent. In all, 11 unique
microbial isolates were found to produce active extracts.

41

PLATE
44
44
44
45
45
45
45
45
45
45
45
45
45
45
47
48
48
50
50
51
54
54

WELL
G02
G03
G07
A02
A03
B01
B02
B03
B11
C01
C02
C03
C06
C07
D08
F06
G01
B03
B04
A01
D04
D05

FRACTION
V663-SYZ
V663-SYZ
V668-SYZ
V663-RM
V663-RM
V671-RM
V671-RM
V672
V881-SYZ
V881-SYZ
V881-PDBS
V881-PDBS
V881-RM
V881-RM
Z691-SYZ
V876-QS-MB
V877-MB
W305-SYZ
W305-SYZ
W523-RM
E677-KP/HP20
E677-SYZ/HP20

SOLVENT
MEOH
CH2CL2
CH2CL2
HEPTANE
ETOAC:ETOH
ETOAC:ETOH
MEOH
MEOH
MEOH
CH2CL2
MEOH
CH2CL2
ETOAC:ETOH
MEOH
CH2CL2
CH2CL2
CH2CL2
MEOH
CH2CL2
ETOAC:ETOH

TOTAL # OF DIFFERENT FRACTION SOURCES

OTHER WELLS TO CONSIDER
44.G04,G05
44.G04,G05
44.G06,G08,G09
45.A11
45.A11
45.B04,B05,B06,B07

45.C05
45.C05
47.D09
48.F03,F04,F05
48.F11,G03
50.B05,B06
50.B05,B06
50.H11,51.A02
11

Table 3: Active marine microbial extracts at 1 µg/mL.
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Dose-Response Analysis of Fractions from Active Isolates
Dose-response analysis in P. falciparum Dd2 was performed on all samples from each
microbial isolate that yielded at least one active extract (46 in total). IC50 values calculated using
GraphPad Prism ranged from 0.04 µg/mL (40 ng/mL) to > 2.5 µg/mL. Of the 46 samples, 18
extracts had IC50 ≤ 1 µg/mL and were classified as potent extracts (overall hit rate 1.8%). Many
extracts had an IC50 > 2.5 µg/mL, indicating that normalized data obtained during SYBR Green
I dose-response screening demonstrated < 50% inhibition at 2.5 µg/mL, the highest screening
dose. Table 4 summarizes the results of these analyses.
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Well
45-A02
44-G02
45-A03
44-G03
44-G04
44-G05
45-A04
44-G07
44-G06
44-G08
44-G09
45-B02
45-B01
45-A11
45-B03
45-B04
45-B05
45-B06
45-C01
45-B11
45-C06
45-C07
45-C02
45-C03
45-C05
47-D08
47-D10
47-D07
47-D09
48-F06
48-F03
48-F04
48-F05
48-G01
48-F11
48-G02
48-G03
50-B03
50-B04
50-B05
50-B06
51-A01
50-H11
51-A02
54-D05
54-D04

Isolate ID

V663

V668
V671
V672

V881

Z691

V876

V877

W305
W523
E677

IC50 in Dd2 (µg/mL)
0.89
0.91
1.45
>2.50
>2.50
>2.50
>2.50
>2.50
>2.50
>2.50
>2.50
0.88
>2.50
>2.50
1.47
>2.50
>2.50
>2.50
0.06
0.10
0.10
0.10
0.35
0.83
>2.5
0.05
0.72
>2.50
>2.50
>2.50
>2.50
>2.50
>2.50
>2.50
>2.50
>2.50
>2.50
0.42
1.10
1.39
>2.50
>2.50
>2.50
>2.50
0.04
0.41

≥ 70% Inhibition at
1 µg/mL

Table 4: Dose-response analysis of extracts from active isolates in Dd2.
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Y
Y
Y
Y
N
N
N
Y
N
N
N
Y
Y
N
Y
N
N
N
Y
Y
Y
Y
Y
Y
N
Y
N
N
N
Y
N
N
N
Y
N
N
N
Y
Y
N
N
Y
N
N
Y
Y

Cytotoxicity and Selectivity of Representative Extracts
To avoid redundancy, the extract from each source organism that exhibited the most
potent activity against Dd2 (≥ 70% inhibition at 1µg/mL and lowest IC50) was selected as the
representative extract for its respective microbial isolate. The 11 representative extracts
(highlighted in Table 4) were counter-screened against the NIH/3T3 murine embryonic
fibroblast cell line in order to evaluate mammalian cell cytotoxicity. Dose-response analysis
using the MTS cell proliferation assay from Promega yielded IC50 values ranging from 9.1
µg/mL to 29.1 µg/mL. Mammalian cytotoxicity, antiplasmodial potency, and the name or
description of each active isolate are summarized in Table 5. Calculation of selectivity index
reveals that the representative extracts display up to 773-fold selective toxicity for multidrugresistant P. falciparum over embryonic mouse fibroblasts.
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Extract

IC50 in Dd2
(µg/ml)

Cytotoxicity
(µg/ml)

Selectivity
Index

Source Organism

54-D05

0.04

28.6

772

E677: Actinomycete

47-D08

0.05

27.2

555

Z691: Penicillium sp.

45-C01

0.06

29.1

469

V881: Streptomyces sp.

50-B03

0.42

9.3

22

W305: Orange Actinomycete

45-A02

0.89

10.2

11

V663: Orange/Brown Actinomycete

45-B02

0.88

9.1

10

V671: Nocardiopsis sp.

45-B03

1.47

9.3

6

V672: Yellow Actinomycete

48-G01

>2.50

28.1

≤ 11

V877: Marinobacter sp.

51-A01

>2.50

10.2

≤4

W523: Hortea werneckii

48-F06

>2.50

9.4

≤4

V876: Marinobacter salsuginis

44-G07

>2.50

9.3

≤4

V668: Yellow Actinomycete

Table 5: Cytotoxicity and selectivity of extracts from active isolates.
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Discussion
The results of this project support the use of the malaria SYBR Green I fluorescencebased protocol (MSP) as a reliable assay in antiplasmodial screening and dose-responses
analysis. Although a Z-factor ≥ 0.7 was set as the criterion for analysis of data, all Z-factors
obtained from SYBR Green I and MTS assay plates were ≥ 0.8, and most were ≥ 0.9. This
indicates conditions close to ideal in the assay protocol described, with high reliability of
results. Other studies utilizing a similar MSP also report high Z-score values [66]. These
findings are consistent with validation studies that demonstrate reliable relationships between
SYBR Green I fluorescence, radioactive isotope incorporation signals, and directly visualized
parasitemia [70]. It should be noted that the experiments performed in this project are subject to
the usual limitations in consistency when asynchronous cultures are used, and to selection
against apicoplast inhibitors due to the 72-hour incubation time with test extracts [52].
Studies that involve screening for antiplasmodial activity vary widely in the
composition of samples screened, the strain of Plasmodium targeted, the screening assay used,
and the definition of “hits” [71]. The results of this project are also difficult to compare with
those from a preliminary study performed in Dr. Chakrabarti’s lab, which screened 176 marine
microbial extracts. The hit rate from the previous study was 9.1%, but with “active extract”
parameters of ≥ 75% inhibition at a concentration of 5 µg/mL. The present study utilized a twostep process to minimize the number of false positives selected for dose-response analysis, and
to increase the probability that calculated IC50 values would be ≤ 1 µg/mL. Accordingly,
concentrations of 10 µg/mL and 1 µg/mL were screened, rendering it impractical to compare
the 2.2% hit rate from this project to that in the preliminary study.
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In the preliminary study, 6 of 176 fractions had IC50 ≤ 1 µg/mL, a hit rate of 37.5% in
active extracts (3.6% overall). In this project, 16 potent fractions (IC50 ≤ 1µg/mL) yielded a hit
rate of 72.7% in active extracts. It is likely that the second, more rigorous screening increased the
hit rate in active extracts by eliminating many false positives. Two additional potent fractions,
which did not exhibit ≥ 70% inhibition at 1 µg/mL but were assayed due to their source
organism, bring the total to 18, or 1.8% hit rate overall. This 50% decrease in hit rate has many
possible explanations, beginning with the variable composition of marine microbial extracts.
Biosynthesis of active compounds is difficult to predict, although taxonomical diversity may
lead to chemical diversity. Accordingly, biodiversity could have been limited by multiple
fermentation and extraction methods that did not significantly induce production of unique
metabolites, resulting in extracts of similar composition (essentially duplicates).
The smaller overall hit rate may also reflect the susceptibility of two-step screening to
false negatives. Since the IC50 cutoff for potency was identical to the screening concentration (1
µg/mL), potent extracts (fractions 47-D10 and 50-B5, and possibly others) were eliminated in
the second step (Table 4). For these 2 fractions, more potent extracts from the same isolate
compensated for false negatives and were selected as representative fractions. However, 45-B2
and 45-B3 were the only potent extracts from their isolates (Table 4), suggesting that each
undetected false negative could represent a missed active isolate. Although the two-step screen
was effective in reducing false positives, performing the second screen at a higher concentration
(perhaps 2 µg/mL), may have increased hit rate of potent fractions and active isolates. Since
insoluble fragments in suspension can be difficult to accurately dilute, a higher concentration of
crude extracts is also more uniform in composition, increasing the consistency of results.
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Of the 11 marine isolates that produced active extracts, 7 were found to yield fractions
with potent activity against Dd2. In particular, extracts from V881, Z691, and E677 exhibited
IC50 on the order of ng/mL. Although the crude extract suspensions were diluted to extremely
small concentrations for dose-response analysis, data confirmed that the extracts were at least
more active than chloroquine (IC50 ~100 ng/mL) in drug-resistant Dd2 [66]. Additionally, the
high selectivity indices of these fractions indicate that the active compounds in these extracts
can possibly inhibit parasitic growth without significant harm to host tissue. The 4 source
organisms whose “active extracts” had < 50% inhibition at 2.5 µg/mL were false positives, since
each performed well in the second screen. Possible causes include inadequate dilution or poor
parasite growth during the second screen, and alteration of active compounds through
metabolism or deterioration (i. e., high IC50 is a false negative).
The hit rate of 1.8% in this project is almost double the hit rate of 1% yielded by a similar
screening of crude marine extracts. Cervantes et al. utilized an MSP HTS, identical Z-factor
analyses, and similar parameters for calculating hit rate (IC50 ≤ 1 µg/mL), but screened fractions
from both invertebrates and microorganisms [71]. The present study exclusively screened
extracts from deep-sea marine microbes, some of which are novel, previously unidentified
species. Microorganisms were fermented in unique conditions intended to induce biosynthesis
of secondary metabolites, and extractions were prepared using various solvents. Both the
diversity of aquatic microorganisms and variety of novel extraction methods may have
contributed to a higher overall hit rate in the current project compared to other natural product
screens. Overall, these findings support the prediction that antiplasmodial compounds can be
identified through screening and counter-screening of marine microbial extracts.
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Multi-step screening of 1,000 marine microbial extracts, dose-response analysis of
extracts from active isolates, and counter-screening of selected extracts comprise the scope of
this project. However, the identification of potent, selective extracts will help prioritize these
extracts for identification of secondary metabolites that are responsible for antiplasmodial
activity. Collaborators at HBOI will analyze the composition of extracts through liquid
chromatography and mass spectrometry (LC-MS) with the goal of preparing fractions that can
be screened further against Dd2 and 3T3. Structures of purified compounds with low IC50 in
Dd2 and ≥ 100-fold selectivity over 3T3 can be elucidated through nuclear magnetic resonance
(NMR) (Figure 10). If dereplicated from existing antiplasmodial molecules, these lead
compounds can potentially be used as scaffolds for antimalarial drugs.
Once an inhibitor is identified, investigation of its specific mechanism of action can
occur concurrently with development for clinical use [7]. After treatment of synchronized P.
falciparum culture with ≥ IC90 of the inhibitor, time point imaging can reveal morphological
changes or stage-specific inhibition through the erythrocytic stages [72]. Metabolic screening
against known enzymes, including DHODH, can reveal interactions with priority targets [45].
Affinity chromatography (AC) requires high binding rates, but with the inhibitor as bait, AC
may help identify interactions with putative target proteins [73]. In silico cluster analysis of
structural similarity can classify compounds under existing drug chemotypes, which can be
helpful if the chemotype and its target have been previously identified [47]. Finally, drugresistant strains can be generated in vitro and genomic analysis performed to identify mutations:
comparison to PlasmoDB [74] may reveal target proteins through drug resistance mechanisms
[75].
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